Posted by AGORACOM
at 8:49 AM on Wednesday, December 2nd, 2020
Toronto, Ontario–(Newsfile Corp. – December 2, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“) is pleased to announce it has partnered with model and influencer, Khloë Terae, who has an extensive social media following which includes 2.4 million followers on Instagram (@Khloë ), 2.2 million likes on Facebook, and 647,000 followers on Twitter. Khloë has appeared in Playboy, MAXIM, Sport Illustrated, walked runways in Paris, LA, Miami, NYC, & Toronto, and has appeared on numerous Billboard ads in Beverly Hills, Las Vegas & West Hollywood.
“We are very excited to work so closely with Khloë, who on top of being a world famous model and influencer, is an incredible spokesperson for Autism Speaks and is an all-around great human! Red Light Holland’s core belief is to work with good-natured, empathetic, spiritual, fun and energetic people. We respect Khloë’s social media expertise, her ability to connect with millions of people on a daily basis and we embrace her stylistic integrity,” said Red Light Holland CEO and Director, Todd Shapiro. “We are proud to align ourselves with Khloë – she is candid, cool and engaging – we’re pumped for her to model RLH merch!”
“I’m ecstatic to be partnering with Red Light Holland and the Company’s progressive movement. I’ll be proud to model and promote the Company’s clothing to millions of my followers, in many different settings. I’m Canadian, so I especially love the toques!” said Khloë Terae. “I also look forward to working with Russell Peters and Todd Shapiro and their ultimate vision while assisting in social media growth, brand awareness, and brand development.”
In light of the partnership, Red Light Holland issued Khloë 200,000 stock options (the “Options“) pursuant to the Company’s stock option plan, with 100,000 of the Options vesting immediately upon issuance. The remaining 100,000 shall vest six (6) months following issuance. Each Option allows for the purchase of additional common share in the capital of the Company and shall be exercisable at $0.10. The Options shall be exercisable until December 1, 2023.
About Khloë Terae:
Khloë was born in Toronto, Canada and currently resides in Los Angeles. Khloë considers the world her oasis, as at a young age she was fortunate to have travelled to over 50 countries.
Khloë’s has been featured in Playboy, MAXIM, Sports Illustrated & countless other publications, along with major media campaigns for world-renowned brands which included a handful of billboard advertisements in Beverly Hills, Las Vegas & West Hollywood.
Her experience as a world class model has allowed her to walk the runway of many Fashion Week series, such as Paris, LA, Miami, NYC, & Toronto.
Khloë is also an advocate for raising autism awareness via Autism Speaks.
About Red Light Holland Corp.
The Company is an Ontario-based corporation positioning itself to engage in the production, growth and sale (through existing Smart Shops operators and an advanced e-commerce platform) of a premium brand of magic truffles to the legal market within the Netherlands, in accordance with the highest standards, in compliance with all applicable laws.
Posted by AGORACOM-JC
at 8:12 AM on Wednesday, December 2nd, 2020
Announced that the manufacturer of 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”) has made available the new testing method and technology with improvements related to testing time.
The qPCR kit has reduced the processing time with a polymerase chain reaction (“PCR”) machine to 45-50 minutes.
This is significant compared to other test kits available in the market for the same category of tests that can take up to 2 hours for similar test results.
As a result, management of the Company anticipates that this will help in the service of the Company’s current projects especially when processing large film crews which will enhance the turnaround times for test results on these multi-million dollar productions.
Toronto, Ontario–(December 2, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that the manufacturer of 1copy™ COVID-19 qPCR Multi Kit (“qPCR kit”) has made available the new testing method and technology with improvements related to testing time.
The qPCR kit has reduced the processing time with a polymerase chain reaction (“PCR”) machine to 45-50 minutes. This is significant compared to other test kits available in the market for the same category of tests that can take up to 2 hours for similar test results. As a result, management of the Company anticipates that this will help in the service of the Company’s current projects especially when processing large film crews which will enhance the turnaround times for test results on these multi-million dollar productions.
The Company also sees a benefit of rapid results as it navigates into the travel industry as it looks at processing passengers at cruise ship terminals, and with airport authorities, to reduce the risk of transmission of the virus. These potential testing projects represent an important shift towards getting the travel industry back on its feet over the next year and supporting business travellers and vacationers looking to safely take a trip abroad.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Investor Webinar
Datametrex also announces that its senior management will be hosting an investor update webinar on Thursday, December 3, 2020, at 1:30 p.m. EST to discuss the Company’s Third Quarter 2020 results, developments, and contracts on the Artificial Intelligence technologies and COVID-19 test kits.
Datametrex plans to answer questions previously sent to [email protected] and during the webinar, at management’s discretion and subject to time constraints.
The Company’s Financial Statements (“FS”)and Management Discussion & Analysis (“MD&A”) are available at the nine months ended September 30, 2020 are available on the Company’s profile at SEDAR at www.sedar.com.
About 1drop Inc.
1copy™ COVID-19 qPCR Kit is approved by Health Canada (“HC”), Kingdom of Saudi Arabia-Saudi Food & Drug Authority (“SFDA”) approval, and CE marking certification (“CE”) for European Economic Area (“EEA”) countries, which covers the 27 member states of the EU, the 4 members of the European Free Tarde Association (the “EFTA”), plus Turkey and the United Kingdom under Brexit. It is a nucleic test kit that verifies RdRp gene for SARS-CoV-2 with the qPCR kit via nasopharyngeal swab and oropharyngeal swab and specifically targeting the E gene sequences of COVID-19. The kits are made by 1drop Inc. located in Jungwon-gu, South Korea, and was incorporated in 2017 following a technology spin-off from Samsung electronica’s C-Lab program. Samsung Electronica’s C-Lab located in South Korea is an internal incubation program that first started in 2012 to help inspire a more creative company culture.
For more information please consult the website at: 1drop
About Datametrex
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact: Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements including in this news release contain “forward-looking information” or constitute “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements or information are provided for the purpose of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy, including the dollar amount of revenue anticipated under the Agreement.
Forward-looking statements or information are based on current expectations, estimates and projections that involve several risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company and described in the forward-looking statements or information. These risks and uncertainties may cause actual results to differ materially from the forward-looking statements or information.
Readers are cautioned that the foregoing list is not exhaustive of all possible risks and uncertainties. Readers are also cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations, and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 7:35 AM on Wednesday, December 2nd, 2020
Announced that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.
In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.
VANCOUVER, BC / December 2, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.
In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.
FDA APPROVED “SPIT AND SHAKE” AT HOME/WORK SALIVA TEST IS A GAME CHANGER
The KAI Saliva Test is the direct result of investing in scientific R&D through KAI, empowering them to deliver clinical trial data and validation. This gives Empower a strong upper hand nationally and now potentially on an international stage.
The power of the Saliva Test is in its simplicity, in which users merely spit into a funnel, then close the funnel with a lid containing a liquid to be mixed with the saliva by simply shaking it for 5 seconds. This saliva based PCR test does not require a medical technician to administer the specimen collection which can be done by the individual, a parent or an administrator. The specimen is returned to KAI Medical Labs from anywhere in the country for processing. KAI will analyze and provide a response within 24 hours through its HIPAA compliant IT system.
Empower Clinics CEO, Steven McAuley stated “The new KAI Saliva Test is an anywhere-based PCR test that is non-invasive and can even be used to test children. It’s simple, effective and can be distributed nationwide with FDA approval using the KAI assay and processing procedures. It is a game changer in its simplicity and we are optimistic about its success.”
The KAI Saliva Test will be available for sale December 15th, with distribution expected to comprise of online access, wholesale programs and available through our clinic group Sun Valley Health.
KAI ABC RT-PCR TEST PROTOCOL TO DIFFERENTIATE BETWEEN INFLUENZA A/B AND COVID-19 (“ABC”) LAUNCHES WITH RECORD ORDER FROM FILM & TV PRODUCTION
LAUNCH DATE OF COVID-19 ABC RT-PCR TEST MAKES KAI A LEADING NATIONAL MEDICAL LABORATORY
Given the fact that household named labs have not been able to begin distributing their form of an ABC PCR test, the KAI launch date and record order for its ABC RT-PCR test makes KAI Medical Labs a national leader in COVID-19 testing. As a result, Empower has filed a trademark for KAI ABC PCR.
Empower CEO McAuley added “The requirements for more diverse and flexible testing protocols solving complex operational requirements for consumers, industry, private and public sectors form the scientific R&D focus for KAI Medical, as we lead trials and validation for the latest COVID-19 tests.”
Having these new simplified and highly accurate “gold standard” RT-PCR tests opens up markets by breaking down barriers to enable industries to get back to business again, while enabling the public sector to deliver the services of the government that countries depend upon.
MULTIPLE BENEFITS OF KAI ABC RT-PCR RANGE FROM EARLY AND CORRECT DIAGNOSIS TO PACKAGED COST SAVINGS
COVID-19 and influenza viruses have a similar disease presentation. They both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death. As such, the benefits of this KAI ABC PCR test protocol being able to differentiate between the Flu and COVID-19 are invaluable as follows:
First, it is vital in the diagnosis and treatment of respiratory pathogens. As most COVID-19 testing now primarily focuses on COVID-19 only, diagnosing the difference between the two will be crucial to treatment, health outcomes, and overall health of the population. Specifically, differentiating the pathogens will help medical professionals quickly diagnose and treat more efficiently & efficaciously.
Second, it is a vital tool in helping slow down the spread of COVID-19. Specifically, the speed of transmission is an important point of difference between the two viruses. Influenza has a shorter median incubation period (the time from infection to appearance of symptoms) than COVID-19. Transmission in the first 3-5 days of illness is a major driver for the spread of viral infections. This makes COVID-19 extremely difficult to contain. This is why testing to differentiate the viral infections becomes critical to “slowing the spread.”
Finally, affordability and efficiency. Though the overall cost of an ABC RT-PCR test is approximately 15% to 25% more expensive than an RT-PCR test, providing analysis on all three viruses is significantly cheaper and more affordable than testing for them separately. Moreover, from an efficiency point of view, simultaneously confirming a patient has the flu and does not have COVID-19 from the same collected specimen, allows them, their families and work colleagues to return to a normal life much faster.
BENEFITS TO EMPOWER CLINICS
From a business development point of view, Empower has a high degree of confidence the multiple benefits listed above will translate into significant new business, as evidenced already by the transition of the Company’s recent $1,000,000 test order by a film & tv production from RT-PCR to the new KAI ABC PCR protocol.
From an R&D perspective, Kai Medical Laboratory is focused on the future and new innovative quality testing to better understand the epidemiology and contagion containment that we have all experienced during this pandemic. Kai Medical will continue to be at the forefront of science and innovative quality care by providing value added services, accuracy, and consistency. As such, we believe more successful R&D product announcements will be made in the near future.
ABOUT EMPOWER
Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 7:30 AM on Wednesday, December 2nd, 2020
The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:
Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
Current assets of C$3.6 million as compared to C$3.2 million;
Total assets of C$3.7 million as compared to C$3.3 million; and
Current liabilities of C$3.07 million as compared to C$1.4 million.
Herzliya, Israel and Calgary, Alberta–(December 2, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce today its financial and business results for the three and nine months period ended September 30, 2020 (the “Financial Statements“) and provide highlights and comments on these results. This news release should be read in conjunction with the Financial Statements and corresponding Management’s Discussion and Analysis available on the Company’s profile at www.sedar.com. The Company’s Financial Statements have been prepared in accordance with International Financial Reporting Standards (“IFRS“).
“This has been a milestone quarter for Innocan. After successfully completing our $5.1M financing, we have laid the groundwork for full commercialization of our CBD based products. We are completing the manufacturing process in Europe and the USA and have received regulatory approvals for marketing in Europe and the USA” stated Iris Bincovich, Chief Executive Officer of Innocan.”
Business highlights for the three months period ended September 30, 2020
On June 5, 2020, the Company announced the commencement of commercial production of its Derma CBD line in Portugal. The first product currently being manufactured is the patent pending Relief & Go Pain Relief spray.
On June 26, 2020, the Company announced the results from the first dermal clinical study of the Relief & Go and SHIR product lines. The double-blind, randomized control study assessed the tolerance degree of the Company’s CBD topical products and demonstrated the products to be non-irritating to the skin.
On July 9, 2020, the Company announced its collaboration with Recipharm, Israel (“Recipharm“) to synthesize and analyze cannabinoid loaded exosomes. Recipharm unites more than 30 facilities across 10 countries offering a range of services with a focus on two areas of operation: pharmaceutical development services and manufacturing services.
On July 13, 2020, the Company announced that it received notice from the U.S. Food and Drug Administration that Innocan’s over-the-counter Relief & Go Pain Relief spray received technical validation and approval to commence marketing in the USA. Innocan’s pain relief formulation contains a combination of magnesium oil, methyl salicylate, menthol and CBD. The Relief & Go Pain Relief spray is designed to target and relieve pain related to muscles and joints. The unique formulation is administered with a simple dose by spray, roll-on or lotion.
On August 6, 2020, the Company announced that its SHIR CBD Derma Cosmetic product line successfully passed safety assessments in accordance with European Union (EU) cosmetic regulation No. 1223/2009 and received an EU Cosmetic Product Safety Report for marketing in the European Union.
On August 11, 2020, the Company announced it entered into a manufacturing and distribution agreement (the “ESI Agreement“) with Endless Sky Incorporated (“ESI“), a large-scale Canadian cannabis extractor based in Calgary, Alberta. Under the ESI Agreement, ESI will serve as the exclusive distributor of Innocan’s CBD products in Canada under a license granted by Innocan. ESI will manufacture Innocan’s CBD products at ESI’s Health Canada licensed facility in Redvers, Saskatchewan. ESI’s manufacturing and distribution rights consist of the Relief & Go Pain Relief spray and cream and the SHIR Eye Serum, Face Cream and Night Cream. The ESI Agreement is conditional upon ESI receiving Health Canada approval no later than December 31, 2020. According to the ESI agreement, ESI shall pay Innocan a cash license fee per product as well as royalties based on net sales of the products distributed by ESI. The ESI Agreement is for a term of 12 months and will be automatically extended for additional periods of 12 months, each based on ESI achieving minimum sales targets for the previous 12-month period.
On August 19, 2020, the Company entered into a manufacture and supply agreement with GNB Swiss Investments SA to manufacture and supply GNB Swiss Investments SA products based on Innocan’s formulas, which will be distributed by GNB Swiss Investments SA under its own brand.
On August 20, 2020, the Company announced that Innocan entered into a distribution agreement (the “Cloud 9 Agreement“) with Cloud 9 Switzerland LLC (“Cloud 9“) to sell the Company’s SHIR Beauty and Relief & Go product lines in Italy and Switzerland. Under the terms of the Cloud 9 Agreement, Cloud 9 will distribute Innocan’s unique cosmetic CBD products in Italy and Switzerland on a nonexclusive basis. The Cloud 9 Agreement defines the ordering and delivery mechanisms for the products and the marketing cooperation between the parties. The parties intend to carry out the Cloud 9 Agreement immediately, following the completion of all registration and regulatory requirements in Italy and Switzerland.
On September 15, 2020, the Company announced it completed a cosmetic clinical study examining the impact of its SHIR Premium CBD Facial Serum, containing 300 mg of cannabidiol, on skin hydration.
Financial highlights for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:
The following are financial highlights of Innocan’s operating results for the three months period ended September 30, 2020, compared to the three months period ended September 30, 2019:
Research and development expenses amounted to C$654,000 for the three months period ended September 30, 2020 compared to C$149,000 for the three months period ended September 30, 2019. The increase is primarily attributable to an increase in research expenses due to the new research agreements entered into during the nine months period ended September 30, 2020 with Yissum Research Development Company and Ramot at Tel Aviv University, along with an increase in patent application expenses.
Selling, general and administrative expenses amounted to C$902,000 for the three months period ended September 30, 2020 compared to C$1,858,000 for the three months period ended September 30, 2019. The decrease in selling, general and administrative expenses is primarily attributable to the reduction of issuance expenses.
The following is a summary of key balance sheet items as of September 30, 2020, as compared to figures as at December 31, 2019:
Cash and cash equivalents were C$2,393,060 as compared to C$2,569,602;
Current assets of C$3.6 million as compared to C$3.2 million;
Total assets of C$3.7 million as compared to C$3.3 million; and
Current liabilities of C$3.07 million as compared to C$1.4 million.
About Innocan
The Company is a pharmaceutical tech company that focuses on the development of several drug delivery platforms containing CBD. Innocan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus using CBD. CBD-loaded exosomes hold the potential to help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.
Innocan signed a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem, to develop a CBD drug delivery platform based on a unique controlled release liposome to be administrated by injection. Innocan plans, together with Professor Berenholtz, Head of the Laboratory of Membrane and Liposome Research at the Hebrew University, to test the liposome platform on several potential indications. Innocan is also working on a dermal product that integrates CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution regarding forward-looking information
Certain information set forth in this news release, including, without limitation, information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedar.com.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Posted by AGORACOM-JC
at 10:03 AM on Tuesday, December 1st, 2020
Else has achieved both a quality product and has established production lines in anticipation of significant ramp-up in sales during 2021.
In Q3 the company focused on: preparing the product for an initial soft launch into the U.S. markets via online and in retail channels, growing the brand awareness and obtaining the funding necessary for full-scale commercialization of the product line.
The Company completed the first two (2) commercial manufacturing runs of Else Complete Nutrition for Toddlers powder product.The Company launched online sales in North America on www.elsenutrition.com and on Amazon.com.
In October, the Company completed a C$25.7 million financing (the financing closed on October).
VANCOUVER, BC , Nov. 30, 2020 – ELSE NUTRITION HOLDINGS INC. (TSXV: BABY ) (OTCQX: BABYF ) (FSE: 0YF ) (“Else” or the “Company”) the plant-based baby, toddler and children nutrition company , today announced results for its third quarter ended September 30, 2020 .
The following will summarize our major achievements in the third quarter of 2020, as well as our business. Full financial results can be found in the Company News section of our website at https://elsenutrition.com/pages/investor-relations .
Q3 2020 Financial Highlights
Else has achieved both a quality product and has established production lines in anticipation of significant ramp-up in sales during 2021.
In Q3 the company focused on: preparing the product for an initial soft launch into the U.S. markets via online and in retail channels, growing the brand awareness and obtaining the funding necessary for full-scale commercialization of the product line.
The Company completed the first two (2) commercial manufacturing runs of Else Complete Nutrition for Toddlers powder product.
The Company launched online sales in North America on www.elsenutrition.com and on Amazon.com.
In October, the Company completed a C$25.7 million financing (the financing closed on October).
Operating loss was C$2,779 thousand , compared to C$1,056 thousand in the third quarter of 2019.
Net loss was C$3,930 thousand , or C$0.05 per share, compared to C$1,058 thousand , or C$0.02 per share in the third quarter of 2019.
Cash flow used for operating activities was C$2,965 thousand , compared to C$2,089 thousand in the third quarter of 2019.
Cash position was C$5.1 million as of September 30, 2020 (does not reflect the October financing for C$25.7 million ).
Nine Months Financial Highlights
The company started its operation in June 2019 so there are no comparable figures from 2019.
Operating loss was C$5,578 thousand .
Net loss was C$10,076 thousand , or C$0.13 per share.
Cash flow used for operating activities in the first nine months of 2020 was C$5,612 thousand .
Hamutal Yitzhak , Else CEO, commented: “I am very proud of our achievements this quarter. Although COVID-19 caused a slowdown on many fronts, we succeeded to complete two commercial manufacturing runs, package our product, launch our marketing campaign and start selling our revolutionary Plant-Based Complete Nutrition for Toddlers product in North America on our e-store and on Amazon.com. We also made significant progress on many other fronts, including the hiring of several retail brokers, listing on several natural food retail chains, onboarding to KeHE distributors, product development, clinical research, and more. By the end of the quarter we also completed our third and largest funding round ( C$25.7 million ), securing funds for operations for the next 18 months. We are very happy with the growth rate of our online sales since we launched, and with the progress we are making in the retail channel.”
Impact of COVID-19
We experience the effect of the pandemic in all areas of our business, from delays in raw material deliveries, to clinical and product development projects. Due to lockdowns and other COVID-19 related measures all our business meeting, marketing events, conferences and expos were either canceled or turned virtual, slowing down the pace of our business development efforts.
Revenue Distribution for Q3 2020
The Baby Snacks business line in Israel represented 44%, Baby Bottles and Accessories business line in Israel represented 26% and the Else Formula business represented 30% of total revenues.
As we started selling our Else Complete Nutrition For Toddler products (singles and 4-packs of 22oz cans of powder) online on our e-store ( www.elsenutrition.com ) on August 12 , our revenue from this channel represent the first few weeks of sales only, and amounted to C$109 thousand .
We started selling the same products also on Amazon.com on September 20 , and during these few days we completed well over 100 first sales which amounted to $C5 thousand . Sells to retail stores did not commence in Q3, so no revenue was recorded yet from this channel.
Revenue Distribution for Nine Months 2020
The Baby Snacks business line in Israel represented 44%, Baby Bottles and Accessories business line in Israel represented 43% and the Else Formula business represented 13% of total revenues.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel -based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan . The holding company, Else Nutrition Holdings Inc., is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School , USA , Tel Aviv University , Schneider Children’s Medical Center of Israel , Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium .
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company’s financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that there will be no interruptions or supply chain failures as a result of COVID 19 and that the manufacturing, broker and supply logistic agreement with the Company do not terminate. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Posted by AGORACOM-JC
at 9:34 AM on Tuesday, December 1st, 2020
TORONTO, Dec. 01, 2020 – Blockchain Foundry Inc. (“BCF” or the “Company”) (CSE:BCFN), a leading North American blockchain development firm, is pleased to report its financial results for the three and nine months ended September 30, 2020. The Company’s full Financial Statements and Management Discussion & Analysis (“MD&A”) are available at www.sedar.com . All amounts are reported in Canadian dollars unless otherwise stated.
Financial Highlights
The following table summarizes revenue and net income (loss) for the three and nine months ended September 30, 2020 and September 30, 2019.
Three monthsended September30, 2020
Three months ended September 30, 2019
Change
Percentage Change
Revenue
227,410
214,744
12,666
6%
Net Income
74,334
38,935
35,399
91%
Ninemonthsended September30, 2020
Nine months ended September 30, 2019
Change
Percentage Change
Revenue
1,124,081
526,714
597,367
113%
Net Income (Loss)
141,974
(467,322)
609,296
not meaningful
“In Q3 2020, BCF achieved positive net income and an increase in revenue compared with Q3 2019. This outcome was a direct result of increased client development activity as well as growing market acceptance of blockchain technology. The Company has five active clients in various project stages, and our pipeline is robust. We have also taken the opportunity to capitalize the business over the last few months. We are well positioned to continue expanding our consulting business and begin to explore product opportunities that take advantage of our significant expertise in the blockchain space,” said Dan Wasyluk, CEO of Blockchain Foundry.
Outlook
The Company continues to develop its suite of blockchain infrastructure technology products and build its blockchain development and advisory business.
On the product side, BCF is building core technology to enable highly scalable, low cost, high speed blockchain transactions (Z-DAG), allow users to incorporate multiple blockchain systems within the same project (Syscoin-Ethereum bridge), and initialize custom blockchain tokens (Spark Wallet). BCF’s technology infrastructure is suitable for a variety of use cases where speed, scalability, fees and security are important factors, including stablecoin projects, loyalty applications, digital identities, and remittance services.
On the advisory side, BCF endeavours to work with clients who share the same priorities and vision for what blockchain technology can achieve for governments, businesses and consumers. To date, BCF has worked with clients across industries including digital identity, financial services and token wallet and development infrastructure.
Q32020BusinessHighlightsand Subsequent Events
Entered into a blockchain development agreement with NIX Platform. The agreement has a duration of approximately 6 months and a value of approximately $60,000. For more information please see the Company’s press release dated September 1, 2020.
Entered into a blockchain development agreement with a GDPR compliance solution provider. The initial phase of the agreement has a duration of approximately 4 weeks and a value of approximately $50,000. For more information please see the Company’s press release dated October 5, 2020.
Entered into an agreement for a drawdown equity financing facility of up to $4 million over a 24-month period with Alumina Partners (Ontario) Ltd., a subsidiary of Alumina Partners LLC, a New York-based private equity firm. Subsequently, the Company has drawn down three tranches under this agreement for total gross proceeds of $450,000. For more information please see the Company’s press releases dated October 6, 2020; November 10, 2020; and November 30, 2020.
About Blockchain Foundry Inc.
Blockchain Foundry develops and commercializes blockchain-based business solutions and provides consulting services to corporate clients seeking to incorporate blockchain technology into their businesses.
Certain portions of this press release contain “forward-looking information” within the meaning of applicable Canadian securities legislation, which is also referred to as “forward-looking statements”, which may not be based on historical fact. Wherever possible, words such as “will”, “plans,” “expects,” “targets,” “continues”, “estimates,” “scheduled,” “anticipates,” “believes,” “intends,” “may,” “could,” “would” or might, and the negative of such expressions or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved, have been used to identify forward-looking information.
Forward-looking statements should not be read as guarantees of future events, future performance or results, and will not necessarily be accurate indicators of the times at, or by which, such events, performance or results will be achieved, if achieved at all. Readers should not place undue reliance on such forward-looking statements, as they reflect management’s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BCF are inherently subject to significant business, economic, regulatory, competitive, political and social uncertainties, and contingencies. Many factors could cause BCF’s actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements.Although BCF has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are made as of the date hereof and, accordingly, are subject to change after such date. BCF disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Posted by AGORACOM-JC
at 8:56 AM on Tuesday, December 1st, 2020
Announced it will form a medical advisory board composed of doctors and specialists from around the world to better educate the Company and the public on the health benefits of a plant-based lifestyle.
“In our mission to educate the public on the benefits of a plant-based lifestyle, we value the guidance of experts in the medical and science communities,” said Sean Dollinger , PlantX founder. “We look forward to working with our medical advisory board and using their recommendations to make PlantX a leader in the plant-based industry.”
VANCOUVER, BC , Dec. 1, 2020 – PlantX Life Inc. (the ” Company ” or ” PlantX “) (CSE: VEGA ) (Frankfurt: WNT1) is pleased to announce it will form a medical advisory board (” Medical Advisory Board “) composed of doctors and specialists from around the world to better educate the Company and the public on the health benefits of a plant-based lifestyle.
“In our mission to educate the public on the benefits of a plant-based lifestyle, we value the guidance of experts in the medical and science communities,” said Sean Dollinger , PlantX founder. “We look forward to working with our medical advisory board and using their recommendations to make PlantX a leader in the plant-based industry.”
The Medical Advisory Board will meet with PlantX once a month to review its products, meals, recipes and plants, and then make recommendations on how each will affect consumers’ health and wellness. The Medical Advisory Board will also discuss advancements in the plant-based industry and how the Company can capitalize on such advancements.
As a company promoting health, wellness and the benefits of a plant-based lifestyle, PlantX is making an effort to always have the most accurate and up-to-date information to make its online platform the preferred resource for the plant-based community. The Company’s customers will be encouraged to write in with questions, some of which will be answered by members of the Medical Advisory Board in upcoming blogs and podcasts to be made available on www.PlantX.com and www.PlantX.ca .
PlantX Medical Advisory Board
The Medical Advisory Board will consist of the following members:
Thomas A. Burdon , MD, is a Professor of Cardiothoracic Surgery at Stanford University and Chief of Surgery at the VA Palo Alto in California . He is an active surgeon and also supervises more than 150 staff that perform 6,000 surgical cases a year. Dr. Burdon’s commitment to improving the quality of life for his patients encompasses corrective and palliative surgical techniques, as well as providing dietary information and other methods to ameliorate and improve lifestyle habits. He is known by his colleagues and patients for the “Dr. Burdon Diet”, which has helped many in his work environment.
Dr. Katie Cooper is a doctor of psychology based out of London, England , and the author of the book Plant Therapy , which focuses on the well-being benefits of plants and the negative effects that an indoor lifestyle can have on mental health. After seeing how powerful plants could be as therapeutic tools with clients, Dr. Cooper went on to launch Bloomboxclub Limited, a successful plant subscription service in the UK, which is now a part of the PlantX family.
Edward Tam , MD, FRCPC, is a clinical hepatologist. His full time clinical practice is in Vancouver, BC , where he is also active in clinical research, teaching, education, and community outreach. He has a focused interest in the area of non-alcoholic fatty liver disease, including the intersection of how lifestyle and pharmacotherapeutic interventions may address this growing epidemic.
Paul Gross , MD, is a family physician working in downtown Vancouver . He completed medical school at McGill University and residency at St. Paul’s Hospital. Most of his clinical practice is concentrated at Spectrum Health, a multidisciplinary primary care clinic in downtown Vancouver that provides full-service care with an emphasis on the LGBTQ community.
Eva Weinlander , MD, is a Clinical Professor in the Department of Medicine, Division of Primary Care and Population Health at Stanford Health Care. She is a seasoned family medicine physician with a passion for high-quality primary care, medical education, primary care research and healthcare professional wellness.
“At PlantX, we want everyone to have access to the important information regarding health and wellness so they can implement it into their lives,” said Julia Frank , PlantX CEO. “Having medical professionals reinforce the benefits of plant-based living will only further what we can do as a company.”
“I am so excited about the opportunity to partner with the PlantX community, to share my conviction on the power of a healthy lifestyle and provide thoughtful and informed recommendations on how best to support that exploration, regardless of where one is in that journey,” said Dr. Eva Weinlander .
PlantX will continue to expand its verticals on both its Canadian and U.S. e-commerce platforms, with plans to globally grow its platforms and offerings in its promotion of plant-based health, wellness, lifestyles and education.
Non-Brokered Private Placement
The Company is also pleased to announce that it intends to complete a non-brokered private placement of up to 18,181,818 units of the Company (” Units “) at a price of CAD$0.55 per Unit for gross proceeds of up to CAD$10,000,000 (the ” Offering “). In addition, the Company may, at its sole discretion, issue an over-allotment of up to 2,727,273 Units for additional gross proceeds of up to CAD$1,500,000 should demand for the Offering prove higher than expected.
Each Unit will be comprised of one (1) common share (a ” Common Share “) of the Company and one (1) Common Share purchase warrant of the Company (a ” Warrant “). Each Warrant will entitle the holder to acquire one (1) Common Share of the Company for a period of 24 months from the date of issuance of the Warrant (the ” Warrant Expiry Date “), at an exercise price of CAD$0.75 . In the event that the trading price of the Common Shares on the Canadian Securities Exchange (or such other Canadian stock exchange on which the Common Shares are listed for trading) equals or exceeds CAD$2.00 per Common Share for any period of 10 consecutive trading days, the Company may, at its option, within 10 business days following such 10-day period, accelerate the Warrant Expiry Date by issuing a press release (a ” Warrant Acceleration Press Release “), and, in such case, the Warrant Expiry Date shall be deemed to be 5:00 p.m. ( Vancouver time) on the 30th day following the issuance of the Warrant Acceleration Press Release.
The Company intends to use the net proceeds from the Offering for business operations and expansion of its business, and for general working capital purposes. The Offering may close in tranches and will be led by PlantX founder, Sean Dollinger , who will commit CAD$500,000 towards the Offering.
Although the Offering will be non-brokered, the Company may, as compensation to dealers and individuals that introduce subscribers to the Company (each a ” Finder “), and subject to regulatory approval: (i) pay a cash finder’s fee to each Finder equal to 7% of the aggregate gross proceeds of the subscribers introduced to the Company by such Finder; and (ii) issue non-transferable Common Share purchase warrants to each Finder (with terms identical to the Warrants issued under the Offering) equal to 7% of the aggregate Units of the subscribers introduced to the Company by such Finder.
The securities issued in connection with the Offering will be subject to a four-month hold period, in accordance with applicable securities laws.
About PlantX Life Inc.
As the digital face of the plant-based community, PlantX’s platform is the one-stop-shop for everything plant-based. With its fast growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the Company currently has plans underway to expand its product lines to include cosmetics, clothing, and its own water brand — but the business is not limited to an e-commerce platform. The Company uses its digital platform to build a community of like-minded consumers, and most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs, and brands. The Company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle, and thriving in a longer, healthier, and happier life.
This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. The forward-looking information contained herein includes statements relating to the expected formation of the Medical Advisory Board, the Company becoming a leader in the plant-based industry, the frequency of meetings of the Medical Advisory Board, the Medical Advisory Board answering PlantX customers’ questions in upcoming blogs and podcasts, the expected completion of the Offering, the expected terms and size of the Offering, PlantX founder, Sean Dollinger , committing CAD$500,000 towards the Offering, the proposed use of proceeds under the Offering and the business and strategic plans of the Company.
By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this press release including, without limitation: the Company’s ability to comply with all applicable governmental regulations including all applicable food safety laws and regulations; impacts to the business and operations of the Company due to the COVID-19 epidemic; a limited operating history, the ability of the Company to access capital to meet future financing needs; the Company’s reliance on management and key personnel; competition; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.
Additional risk factors can also be found in the Company’s continuous disclosure documents which have been filed on SEDAR and can be accessed atwww.sedar.com. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Posted by AGORACOM-JC
at 7:42 AM on Tuesday, December 1st, 2020
Announced that it has signed an agreement with high-end Italian retailer Gruppo Coin (“Coin”) to provide short-term loans to Coin’s social-media-influencer online sales partners.
Coin (https://en.coin.it/), Italy’s largest chain of department stores, was one of the first foreign retailers to recognize and leverage the power of social media influencers to sell their products in the world’s largest retail market.
Chinese influencers are using popular social media platforms such as TikTok, Sina Weibo and WeChat to revolutionize online retail sales. They create entertaining shows broadcasted on the platforms during which they promote and sell products with which they are associated.
A show will typically cost $1,000 to $10,000 to produce, including promoting it to followers, detailing the products and the limited quantities available for the show in order to create a buzz and the FOMO (fear of missing out) factor with their followers
Montreal, Quebec–(December 1, 2020) – Peak Fintech Group Inc. (CSE: PKK) (OTCQX: PKKFF) (“Peak” or the “Company”), an innovative Fintech service provider to the Chinese commercial lending sector, today announced that it has signed an agreement with high-end Italian retailer Gruppo Coin (“Coin”) to provide short-term loans to Coin’s social-media-influencer online sales partners.
Coin (https://en.coin.it/), Italy’s largest chain of department stores, was one of the first foreign retailers to recognize and leverage the power of social media influencers to sell their products in the world’s largest retail market. Chinese influencers are using popular social media platforms such as TikTok, Sina Weibo and WeChat to revolutionize online retail sales. They create entertaining shows broadcasted on the platforms during which they promote and sell products with which they are associated.
A show will typically cost $1,000 to $10,000 to produce, including promoting it to followers, detailing the products and the limited quantities available for the show in order to create a buzz and the FOMO (fear of missing out) factor with their followers. On average, each influencer will produce about 250 shows per year. The average show typically lasts 3 to 4 hours and offers a variety of products. Top influencers are usually able to sell out their inventory of a particular product within the first 10 minutes of the product being presented. Many influencers have achieved celebrity status, and this is rapidly becoming the preferred way to sell a variety of products in China, from cosmetics to clothing to small appliances and everything in between. In addition to the cost of producing the shows, the influencers must provide their large retail partners with a deposit of 20% to 30% of the value of the products they expect to sell for each show. This is where Peak and the Cubeler Lending Hub come into the equation. With today’s announced agreement, Coin’s influencer partners will be eligible to have the cost of producing their shows, their required cash deposits and their entire product orders financed through the Lending Hub. Peak will earn its customary ~ 2% fee of the value of the loans provided for facilitating the transactions.
“We’ve been studying this space for months, identifying some of the top influencers and brand ambassadors on China’s top social media platforms,” commented Peak China CEO Liang Qiu. “We now have a network of almost 55,000 influencers, each either with their own e-Shops or affiliated with at least one e-Shop, over 120M combined followers and a proven track record of being able to effectively move products. With a network of followers more than 3 times larger than the entire Canadian population, we believe we’re well positioned to talk to virtually any retailer or brand around the world to offer an effective gateway into the Chinese retail space,” concluded Mr. Qiu.
“One of Peak’s objectives has always been to serve as a bridge that connects North American investors and businesses to China,” said Peak CEO Johnson Joseph. “We’ve been working very hard behind the scenes for quite a while now on a way to help Canadian businesses either do more business in China or gain access to the Chinese market. Although the agreement announced today is not with a Canadian company, it certainly sets the stage for us to sign similar agreements with Canadian retailers. Our network of influencers is already excited about the prospects of selling ice wine and a variety of uniquely Canadian products not typically available in China. By capitalizing on the power of social media, I think we’re once again proving our ability to innovate and think outside the box when it comes to the many ways in which we can use the Lending Hub for the benefit of small businesses and entrepreneurs.”
Wall Street Reporter’s NEXT SUPER STOCK Livestream – December 3, 2020
Peak will be a featured presenter at Wall Street Reporter’s NEXT SUPER STOCK livestream conference on Thursday, December 3, 2020 at 12:30pm EST. CEO Johnson Joseph will discuss Peak’s agreement with Gruppo Coin, what it means for the Company going forward from an international standpoint and answer investor audience questions. Those interested can click the following link to register and join the livestream: Next Super Stock Livestream Registration.
About Peak Fintech Group Inc.:
Peak Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating in China’s commercial lending industry. Peak’s subsidiaries use technology, analytics and artificial intelligence to create an ecosystem of lenders, borrowers and other participants in China’s commercial lending space where lending operations are conducted rapidly, safely, efficiently and with the utmost transparency. For more information: http://www.peakfintechgroup.com
For more information, please contact:
CHF Capital Markets Cathy Hume, CEO 416-868-1079 ext.: 251 [email protected]
Peak Fintech Group Inc. Johnson Joseph, President and CEO 514-340-7775 ext.: 501 [email protected]
This news release may include certain forward-looking information, including statements relating to business and operating strategies, plans and prospects for revenue growth, using words including “anticipate”, “believe”, “could”, “expect”, “intend”, “may”, “plan”, “potential”, “project”, “seek”, “should”, “will”, “would” and similar expressions, which are intended to identify a number of these forward-looking statements. Forward-looking information reflects current views with respect to current events and is not a guarantee of future performance and is subject to risks, uncertainties and assumptions. The Company undertakes no obligation to publicly update or review any forward-looking information contained in this news release, except as may be required by applicable laws, rules and regulations. Readers are urged to consider these factors carefully in evaluating any forward-looking information.
Posted by AGORACOM-JC
at 7:32 AM on Tuesday, December 1st, 2020
Success of Venue Bubble Solution in Las Vegas Has Also Created Visibility and Opportunity for Loop Travel Bubble Solutions
Announced the successful execution of its “Venue Bubble” solution in two separate live environments hosting NCAA Division 1 basketball teams.
The Loop Insights Venue Bubble solution was 100% successful in containing the bubble.
Moreover, the system did not suffer any outages and user experiences proved to be as seamless as anticipated, leading to overall satisfaction levels surpassing participant expectations and even Loop’s loftiest internal expectations.
VANCOUVER, British Columbia, Dec. 01, 2020 — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick and mortar space, is pleased to announce the successful execution of its “Venue Bubble” solution in two separate live environments hosting NCAA Division 1 basketball teams.
Loop Insights CEO Rob Anson stated, “There is simply no way to overstate the implications of our live environment Venue Bubble successes in Florida and Las Vegas over the past 10 days. With the whole world watching, including professional sports leagues and teams, college sports leagues and teams, world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class. To this end, we have already commenced significant discussions regarding the possibility of Loop protecting and helping to re-open some of North America’s largest sporting events in 2021.”
The #BeachBubble implementation represented the first-ever end-to-end COVID-19 venue solution in a live environment and a major industry milestone given the global demand for venue solutions from enterprise-level organizations around the world. It was naturally extended to #VegasBubble.
bdG Sports CEO, Brooks Downing stated, “We are very excited with the performance and success of both Fort Myers and the Las Vegas Bubbles. The Loop Insights platform provided a great level of security while providing a very user-friendly experience for our participants. We look forward to working alongside Loop in upcoming future events.”
DATA CONFIRMS 100% SUCCESS AT BOTH #BEACHBUBBLE AND #VEGASBUBBLE TOURNAMENTS
With the #BeachBubble tournament having commenced earlier, the following interim statistics from that specific event can be shared with the public, similarities to which are also being generated at #VegasBubble.
Total Locations – 14
Total Enrolled Users – 553
Total Check-Ins – 3,830
Contact Tracing Checks – 2 reports had to be generated for potential infected cases, with tests confirming both were negative.
Conclusion – The Loop Insights Venue Bubble solution was 100% successful in containing the bubble. Moreover, the system did not suffer any outages and user experiences proved to be as seamless as anticipated, leading to overall satisfaction levels surpassing participant expectations and even Loop’s loftiest internal expectations.
SUCCESS OF VENUE BUBBLES CREATES SIGNIFICANT VISIBILITY AND OPPORTUNITY FOR LOOP #TRAVELBUBBLE SOLUTION SUPPORTED BY APPLE AND GOOGLE WALLET
As the resort convention capital of the world, the #VegasBubble provided Loop with the best possible opportunity to showcase its #TravelBubble solution for the global hospitality and travel industry, the latter of which is set to lose $USD 3.3 Trillion as a result of COVID-19.
To this end, Loop has completed all development and applications for the successful launch of its #TravelBubble solution that is completely embedded into one simple user interface – supported by Apple and Google wallet. Specifically, Loop provides a digital Wallet to users and assigns a digital ID to each user for the highest levels of security. Travelers are then able to upload COVID-19 testing results, vaccination certificates, boarding passes, airline loyalty rewards or points, travel insurance, driver’s license, and payments in one interface.
LOOP IS FIRST TO MARKET WITH OPERATIONAL PLATFORM
This complete and ready to deploy solution has garnered greater attention, as a result of the Company’s Venue Bubble success, from large global players who are only beginning to build their solutions, such as IATA, aiming to launch a cross-border solution in the first quarter of 2021.
Loop not only is first to market with a complete operational platform built for deployment, it is also the first to successfully execute its solutions in a large, active, and live environment thanks to the success of the #BeachBubble and #VegasBubble.
This is critical given the fact airlines, who can no longer wait for governments to scale back blanket quarantines to re-build their businesses, have taken the lead to partner directly with hotels and destinations to launch their own private bubbles.
Rob Anson stated, “We are bringing a plug-and-play solution that can plug into any existing platform today. Recent high-level discussions within the airline industry confirm our advanced level of preparedness. Furthermore, we also meet the needs of the various travel bubbles and governments with public health officials looking to endorse the re-opening of economies, including the safe reopening of borders.”
As a result, Loop believes an exponential opportunity to license its entire platform or pieces of it to many potential clients such as IATA, Hotel Chains, Airlines, and Government.
LOOP TRAVEL BUBBLE SOLUTION SOLVES CURRENT QUARANTINE REQUIREMENTS THAT ARE SHUTTING DOWN INTERNATIONAL TRAVEL
As a result of the COVID-19 Pandemic, mandatory 14-day quarantine periods, and the lack of any travel bubble solutions that could reliably track and mitigate the global spread of the virus by plane or cruise ship, countries have been forced to take drastic measures that are leading to significant damage of the global travel industry.
Specifically, as of today, travel restrictions by country are as follows:
50 countries are completely closed
123 countries are partially open with MANDATORY quarantine upon arrival
With governments beginning to use rapid testing as a means of limiting the risks of COVID-19 importation when re-opening their borders to travelers without quarantine measures, Loop provides a means to ensure closed-loop COVID-19 testing and proof of vaccination is available for all international travelers, as well as, the information flow infrastructure needed to enable it.
Without a solution to replace the drastic travel measures currently in place around the world, the United Nations Conference on Trade and Development (UNCTAD) reported that COVID-19 may cost the world tourism sector losses of US$ 3.3 trillion.
In Canada alone, according to Statista, the Canadian tourism industry contributed close to $40 billion to the economy in 2019. This year, the COVID-19 pandemic has had devastating consequences for the industry.
This press release is available on the Loop Insights Verified Forum on AGORACOM for shareholder discussion, questions, and engagement with management https://agoracom.com/ir/LoopInsights
About Loop Insights : Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing, and contactless solutions to the brick and mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.
This news release contains certain statements which constitute forward-looking statements or information. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility and the ability to access sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:25 AM on Tuesday, December 1st, 2020
ImagineAR™ Elves Help Interactive 3D Santa Come into Homes Easily
Using the free ImagineAR™ app on their phones, parents can bring a life-sized talking 3D Santa directly from the North Pole into their living rooms for photos and videos.
NORTH POLE, Dec. 1, 2020 – ImagineAR Inc. (CSE: IP) (OTC: IPNFF) Santa Claus knows how important it is to keep children and families safe and healthy, so for the first time ever, he will enter homes of good little boys and girls via their parents’ smartphones, rather than chimneys. Using the free ImagineAR™ app on their phones, parents can bring a life-sized talking 3D Santa directly from the North Pole into their living rooms for photos and videos.
“Yes, it’s true,” said Santa. “The elves at ImagineAR and I wanted to bring some early holiday cheer to children this year, since social distancing has stopped my visits to shopping malls, stores and special events. We wanted to make sure children could still have their yearly photo with me and could even dance with me in their very own homes,” the jolly one said.
Inspired by the distraught 5-year old daughter of a fellow elf, ImagineAR head elf Alen Paul Silverrstieen and his team got to work. “This little girl wanted to visit Santa before the holidays and while she understood it wasn’t safe, it broke Santa’s heart,” said Silverrstieen. “The big guy was quite clear- make it so parents, grandparents and friends can use their smartphone to bring him directly into the homes of children everywhere for photos. We went a step further with Santa’s magic- using the free ImagineAR app and from the phone, folks can even record video of Santa Claus dancing with their little ones in front of their very own trees to share with family and friends!” he announced proudly.
To have Santa drop in to your home, just download the free ImagineAR app in the IOS App Store or Google Play on your mobile device, select “AR Near Me”, select your preferred Santa experience from the bottom of the screen, and Santa will magically appear right in front of you through your phone. The ImagineAR app has multiple Santa experiences to choose from. “In case a half-eaten cookie and empty glass of milk aren’t enough, we can even provide parents with photographic ‘proof’ that Santa was in their home on Christmas Eve stealthily with his big bag of toys,” whispered Silverrstieen.
“I’m an old guy, set in my ways,” chuckled Santa. “Don’t tell anyone, but I’ll likely still use chimneys, too. But my ImagineAR elves have really outdone themselves..Wishing everyone a very merry Christmas! Ho! Ho! Ho!”
About ImagineAR ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.
For more information or to explore working with ImagineAR, please visit www.imagineAR.com .
We encourage you to do your own due diligence and ask your broker if ImagineAR Inc. (cse: IP) is suitable for your particular investment portfolio*.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward-looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
View original content to download multimedia: 
